Michael R. Minogue, Chief Executive Officer, President & Chairman of the Board
Dr. W. Gerald Austen, Edward D. Churchill Professor of Surgery, Harvard Medical School and the Massachusetts General Hospital
Louis E. Lataif, Dean of the Boston University School of Management
Dorothy E. Puhy, Executive Vice President, Chief Financial Officer and Assistant Treasurer, Dana Farber Cancer Institute
Martin P. Sutter, Managing Director, Essex Woodlands Health Ventures
Henri A. Termeer, Chief Executive Officer, Chairman, and President, Genzyme
Paul G. Thomas, Chief Executive Officer and Founder, Roka Bioscience
Mr. Michael R. Minogue is the Chief Executive Officer, President and Chairman of Abiomed Inc. (NASDAQ: ABMD). Since joining in April 2004, Mr. Minogue changed the corporate strategy and mission to creating breakthrough heart support technologies for high-risk patients to enable safer, more complete minimally invasive procedures, heart muscle recovery and cost-effective patient care. To achieve this goal, Abiomed acquired and developed new technology such as the Impella, Symphony, recovery VADs and other heart support concepts. The Impella platform is based on the world’s smallest heart pumps which can be inserted percutaneously through a small hole in the leg. During Mr. Minogue’s tenure, Abiomed has grown more than five times in revenue and market capitalization and become GAAP profitable with no debt. Pertaining to product development, Abiomed has earned greater than 15 regulatory approvals on new products related to the CE Mark, 510(k), PMA and HDE. Prior to joining Abiomed, Mr. Minogue completed a successful 11 year career at GE Healthcare. He departed GE as the Vice President of Americas Sales and Marketing for the $1B Information Technology business. At GE, Mr. Minogue held various leadership positions in sales, marketing, service, product engineering and software development. The experience includes the diagnostics of diseases from cancer to heart failure and in various technologies such as MRI, CT, PET, X-ray, Cardiology, and Information Technology and Monitoring. Prior to Abiomed and GE, Mr. Minogue served as an infantry officer in the U.S. Army for four years and eight years Individual Ready Reserve, which included multiple distinctions including Airborne, Ranger, Combat and Expert Infantryman’s Badge, Desert Storm Veteran and Bronze Star. He received his Bachelor of Science degree in Engineering Management from the United States Military Academy at West Point and his MBA from the University of Chicago. Mr. Minogue holds three patents, currently serves on the executive board of directors for AdvaMed, was formerly on the board for LifeCell Corporation (LIFC), and provides personal support for organizations helping military veterans and wounded warriors.
Dr. W. Gerald Austen, M.D., has served as a Director of the Company since 1985. Since 1974 he has been the Edward D. Churchill Professor of Surgery at Harvard Medical School and at Massachusetts General Hospital. From 1969 to 1997, Dr. Austen was Chief of the Surgical Services at Massachusetts General Hospital. Dr. Austen is the former President of the American College of Surgeons, the American Association for Thoracic Surgery, the American Surgical Association and the Massachusetts and American Heart Associations. Dr. Austen is a member of the Institute of Medicine of the National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences, an Honorary Trustee of the Massachusetts General Hospital, a life member Emeritus of the Corporation of the Massachusetts Institute of Technology and Chairman Emeritus of the Board of Trustees of the John S. and James L. Knight Foundation.
Mr. Louis E. Lataif joined ABIOMED’s Board of Directors in September 2005. Mr. Lataif is Dean Emeritus of Boston University School of Management where he served from 1991 to 2010. Prior to joining Boston University, he worked at Ford Motor Company for more than 27 years and retired as a corporate officer. He had also served as President of Ford of Europe and has extensive global experience. Mr. Lataif earned a BS from Boston University and an MBA from Harvard University. He is the recipient of three honorary doctoral degrees.
Ms. Dorothy E. Puhy has served as a Director of the Company and chair of its Audit Committee since 2003. Ms. Puhy is currently Executive Vice President, Chief Operating Officer for the Dana-Farber Cancer Institute (“Dana-Farber”). Previously, beginning in 1994, Ms. Puhy served as Dana-Farber’s Chief Financial Officer and Assistant Treasurer. From 1985 to 1994 Ms. Puhy held various financial positions at the New England Medical Center Hospitals, Inc., including Chief Financial Officer from 1989 to 1994.
Mr. Martin P. Sutter is Founder and Managing Director of Essex Woodlands, one of the oldest and largest life sciences/healthcare focused venture capital and growth equity investment firms. Essex Woodlands manages over $2.5 billion of capital, and currently is investing Essex Woodlands Fund VIII, a $900 million fund focused on growth equity and select venture capital investments. Essex Woodlands has offices in New York, London, Palo Alto, Houston and Shanghai. Mr. Sutter has founded a number of successful healthcare and biotechnology companies originating from institutions of the world renowned Texas Medical Center. He has served on numerous past Boards of Directors of public and private companies including ATS Medical which was acquired by Medtronic, Inc., BioForm Medical which was acquired by Merz GmbH & Co KGaA, Lifecell which was acquired by Kinetic Concepts, Inc., St. Francis Medical which was acquired by Kyphon, Inc./Medtronic, Inc., Confluent Surgical which was acquired by Tyco International and Rinat Neurosciences which was acquired by Pfizer, Inc. He currently serves on the Board of Directors of QSpex Technologies and Bioventus.
Mr. Henri A. Termeer served as chairman, president and chief executive officer of Genzyme Corporation for nearly three decades. Mr. Termeer was appointed president of Genzyme in 1983, two years after the company’s founding. He became its chief executive officer in 1985 and chairman in 1988. He retired from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion. Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer is active in the areas of humanitarian assistance, policy issues, and innovation in providing access to health care. Mr. Termeer is a Board member of Massachusetts Institute of Technology Corporation and serves on its Executive Committee, a director of Massachusetts General Hospital, Board member of Partners HealthCare, a member of the Board of Fellows of Harvard Medical School and on the Board of the Biotechnology Industry Organization (BIO). He also serves on the Boards of Abiomed, Inc., AVEO Pharmaceuticals, Verastem, Inc., Medical Simulation Corporation and Moderna Therapeutics. In 2008, he was appointed to Massachusetts Governor Deval Patrick’s Council of Economic Advisors and he is a co-chair of the Leadership Council of the Massachusetts Life Sciences Collaborative. Mr. Termeer is also Chairman Emeritus of the New England Healthcare Institute, a nonprofit, applied research health policy organization he was instrumental in founding. He was elected a Fellow of the American Academy of Arts and Sciences in 1999. Mr. Termeer was Chairman of the Federal Reserve Bank of Boston’s Board of Directors from 2010-2011 and served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America. Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an M.B.A from the Darden School at the University of Virginia. Mr. Termeer has been recognized by several highly regarded organizations for his contributions to the healthcare and entrepreneurial field.
Mr. Paul G. Thomas joined Roka Bioscience, a company focused on the development and commercialization of rapid, accurate and cost-effective molecular assays for biopharmaceutical processing, food safety and other industrial testing applications, as CEO and Founder in September 2009. Mr. Thomas previously served as Chairman, Chief Executive Officer and President of LifeCell Corporation, a publicly traded regenerative medicine company, from 1998 until it was acquired by KCI in 2008. Prior to joining LifeCell, Mr. Thomas held various senior positions during his tenure of 15 years with Ohmeda, a world leader in inhalation anesthetics and acute care pharmaceuticals. Mr. Thomas received his M.B.A. degree from Columbia University Graduate School of Business and completed his postgraduate studies in Chemistry at the University of Georgia Graduate School of Arts and Science. He received his B.S. degree in Chemistry from St. Michael’s College in Vermont.« back to top